News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

What The Delay Of A Promising Muscular Dystrophy Drug Means For Patients, Investors And All Of Biotech


11/13/2013 8:09:56 AM

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

In the late 1990s Regeneron, the biotechnology company based in Tarrytown, NY, was developing a treatment for amyotrophic lateral sclerosis (ALS), better known as Lou Gehrig’s disease, which cause paralysis and then death. The company had synthesized a protein missing in people with the disease, and patients reported amazing improvements in symptoms.

Help employers find you! Check out all the jobs and post your resume.

Read at Forbes


comments powered by Disqus
Forbes
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES